Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 2
2012 5
2013 7
2014 9
2015 2
2016 1
2017 7
2018 12
2019 10
2020 22
2021 30
2022 22
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 35063969

111 results
Results by year
Filters applied: . Clear all
Page 1
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
Heerspink HJL, Oshima M, Zhang H, Li J, Agarwal R, Capuano G, Charytan DM, Craig J, de Zeeuw D, Di Tanna GL, Levin A, Neal B, Perkovic V, Wheeler DC, Yavin Y, Jardine MJ. Heerspink HJL, et al. Am J Kidney Dis. 2022 Feb;79(2):244-256.e1. doi: 10.1053/j.ajkd.2021.05.005. Epub 2021 May 23. Am J Kidney Dis. 2022. PMID: 34029680 Clinical Trial.
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V. Bakris G, et al. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1705-1714. doi: 10.2215/CJN.10140620. Epub 2020 Nov 19. Clin J Am Soc Nephrol. 2020. PMID: 33214158 Free PMC article. Clinical Trial.
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V; CREDENCE Study Investigators. Jardine MJ, et al. J Am Soc Nephrol. 2020 May;31(5):1128-1139. doi: 10.1681/ASN.2019111168. J Am Soc Nephrol. 2020. PMID: 32354987 Free PMC article. Clinical Trial.
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR, McCullough PA, Buse JB, Anderson J. Weir MR, et al. Am J Nephrol. 2020;51(4):276-288. doi: 10.1159/000506533. Epub 2020 Mar 13. Am J Nephrol. 2020. PMID: 32172239 Free article. Review.
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Agarwal R, et al. Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336. Nephrol Dial Transplant. 2022. PMID: 34850173 Free PMC article. Clinical Trial.
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Jardine M, et al. Clin J Am Soc Nephrol. 2021 Mar 8;16(3):384-395. doi: 10.2215/CJN.15260920. Epub 2021 Feb 22. Clin J Am Soc Nephrol. 2021. PMID: 33619120 Free PMC article. Clinical Trial.
Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Kluger AY, et al. Cardiovasc Diabetol. 2019 Aug 5;18(1):99. doi: 10.1186/s12933-019-0903-4. Cardiovasc Diabetol. 2019. PMID: 31382965 Free PMC article. Review.
Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.
Wada T, Mori-Anai K, Kawaguchi Y, Katsumata H, Tsuda H, Iida M, Arakawa K, Jardine MJ. Wada T, et al. J Diabetes Investig. 2022 Jan;13(1):54-64. doi: 10.1111/jdi.13624. Epub 2021 Aug 3. J Diabetes Investig. 2022. PMID: 34212533 Free PMC article. Clinical Trial.
111 results